Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03952078 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 16, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Re-verified, no change to tracked fieldsv10
  2. Trial status: Recruiting to Active, Not Recruiting Site details revised at 22 of 22 sitesv9 Show 1 more changeShow less
    • Site details revised at 22 of 22 sites
  3. Site details revised at 22 of 22 sitesv8
  4. Study sites: 21 to 22v7
  5. Primary completion date: Dec 31, 2021 to Apr 30, 2026 Study sites: 20 to 21 · Completion date: Dec 31, 2022 to Apr 30, 2026v6 Show 2 more changesShow less
    • Study sites: 20 to 21
    • Completion date: Dec 31, 2022 to Apr 30, 2026
Show 4 earlier versionsHide 4 earlier versions
  1. Primary completion date: Dec 31, 2020 to Dec 31, 2021v5
  2. Study sites: 17 to 20v4
  3. Study sites: 1 to 17v3
  4. Site details revisedv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability, and anti-tumor activity of CPI-818 as a single drug.
Trial Details
NCT Number NCT03952078
Lead Sponsor Corvus Pharmaceuticals, Inc.
Conditions T-cell Lymphoma
Enrollment 151 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov